Katsura Yoshiteru, Takeda Yutaka, Ohmura Yoshiaki, Shinke Go, Sakamoto Takuya, Katsuyama Shinsuke, Ikeshima Ryo, Kawai Kenji, Yanagawa Takehiro, Hiraki Masayuki, Oshima Kazuteru, Sugimura Keijiro, Masuzawa Toru, Hata Taishi, Murata Kohei
Dept. of Surgery, Kansai Rosai Hospital.
Gan To Kagaku Ryoho. 2023 Mar;50(3):369-371.
Prognosis of pancreatic cancer is extremely poor due to recurrence in the early postoperative period. However, there are some reports that the prognosis for lung recurrence alone is relatively better than that of others. In this study, we report the cases of lung recurrence alone after radical resection of pancreatic cancer performed at our hospital. Among 255 cases of radical resection of pancreatic cancer performed at our hospital between July 2010 and August 2021, 6 cases in which the initial recurrence site of recurrence was lung alone were included in the study. The median age of the patients was 72 years (62-82), and there were 5 males and 1 female. Four patients had undergone pancreaticoduodenectomy and 2 patients underwent distal pancreatectomy. Four patients received adjuvant chemotherapy, 3 with S-1 and 1 with GEM. No patients underwent surgical resection for recurrence of lung metastasis, and all patients were treated with chemotherapy. The median time to recurrence was 351 days. As initial therapy after recurrence, 3 patients received GEM plus nab-PTX combination therapy and 3 patients received S-1. The median overall survival after recurrence was 1,979 days, and the 1-year and 3-year overall survival rates after recurrence were 100% and 100%, respectively. The prognosis of patients with recurrence of lung metastasis after surgery for pancreatic cancer at our hospital was similarly good as the previous reports.
由于术后早期复发，胰腺癌的预后极差。然而，有一些报告指出，仅肺转移复发的预后相对优于其他情况。在本研究中，我们报告了我院胰腺癌根治性切除术后仅出现肺转移复发的病例。在2010年7月至2021年8月期间于我院接受胰腺癌根治性切除的255例患者中，有6例初始复发部位仅为肺的患者被纳入研究。患者的中位年龄为72岁（62 - 82岁），其中男性5例，女性1例。4例患者接受了胰十二指肠切除术，2例患者接受了胰腺远端切除术。4例患者接受了辅助化疗，3例使用S - 1，1例使用吉西他滨（GEM）。没有患者因肺转移复发而接受手术切除，所有患者均接受化疗。复发的中位时间为351天。复发后的初始治疗中，3例患者接受了吉西他滨联合白蛋白结合型紫杉醇（nab - PTX）的联合治疗，3例患者接受了S - 1治疗。复发后的中位总生存期为1979天，复发后的1年和3年总生存率分别为100%和100%。我院胰腺癌手术后出现肺转移复发患者的预后与既往报告相似，同样良好。
